Browsing by Subject "Acetamides"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Investigation of in vitro antileishmanial activity of moxifloxacin, linezolid and caspofungin on Leishmania tropica promastigotes.
    (2013) Limoncu M.E.; Eraç B.; Gürpinar T.; Özbilgin A.; Balcioǧlu I.C.; Hoşgör-Limoncu M.
    This study aimed to evaluate the potential in vitro anti-leishmanial activities of moxifloxacin, linezolid and caspofungin against Leishmania tropica. In vitro effects of all agents were studied by using the microdilution method. For this purpose, serial dilutions of the aforementioned agents were prepared in concentrations between 4096 μg/mL-0.008 μg/mL. Afterwards, promastigotes incubated in suitable medium were counted with the hemocytometer and adjusted as having a last concentration of 2.5 x 10(6) cells/mL in wells containing medium+antibiotic or antifungal. After incubation live promastigotes were counted with the hemocytometer and inhibitor concentrations (IC(50)) were determined by comparing with the control that contained no antibiotics or antifungal. IC(50) values of moxiloxacin, linezolid and caspofungin were found as 194.7 μg/mL, 896 μg/mL and 235.7 μg/mL, respectively. As a result, moxifloxacin was found to be effective in lower concentrations than the other studied agents against L. tropica promastigotes.
  • No Thumbnail Available
    Item
    Effects of lacosamide “a novel antiepileptic drug” in the early stages of chicken embryo development
    (Springer Verlag, 2016) Mete M.; Gurcu B.; Collu F.; Unsal U.U.; Duransoy Y.K.; Tuglu M.I.; Selcuki M.
    Introduction: Antiepileptic drugs (AEDs) are teratogens and confer a risk of congenital malformation. The estimated prevalence of major congenital malformations such as cardiac defects, facial clefts, hypospadias, and neural tube defects in epileptic women is 4–10 %, which represents a two- to fourfold increase in pregnant women compared to the general population. However, there are no clear data for newer drugs. Lacosamide (LCM), a novel AED, is the first of the third-generation AEDs to be approved as adjunctive therapy for the treatment of partial-onset seizures. There are no data on the pharmacokinetics of LCM during pregnancy, and only some published data have reported on its effects during pregnancy. Methods: In this study, three different doses of LCM (0.12, 0.5, and 1.60 mg in 0.18 mL) were applied under the embryonic disks of specific pathogen-free Leghorn chicken embryos after a 30-h incubation. Incubation was continued for 80 h, at which time all embryos were evaluated macroscopically and microscopically. Results: There was growth retardation in all of the LCM-treated groups. Major malformations increased in a dose-dependent manner and were mostly observed in the supratherapeutic group. Conclusion: Based on our data, LCM may cause growth retardation or major congenital malformations. Nevertheless, more extensive investigations of its reliability are needed. © 2016, Springer-Verlag Berlin Heidelberg.